A Phase 1 interventional study of Evobruitnib and Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)] in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to female participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2025-11-14.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to assess the effect of M2951 on the pharmacokinetics (PK) of a combined oral contraceptive [Ethinyl estradiol/Norethisterone (EE/NET)] in healthy female participants.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received combined oral contraceptive (COC) \[0.03 milligrams (mg) of Ethinyl Estradiol (EE)\], 0.5 mg of Norethisterone (NET)\] orally on Day 1 and 15 in combination with Evobruitnib at a dose of 45 mg orally twice daily on Days 4 to 17.
Drug: Evobruitnib · Drug: Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]
Participants received Evobruitnib at a dose of 45 mg orally twice daily on Days 4 to 17.
Drug page: Contraceptives, Oral, Combined
Participants received combined oral contraceptive (COC) \[0.03 milligrams (mg) of Ethinyl Estradiol (EE)\], 0.5 mg of Norethisterone (NET)\] orally on Day 1 and 15.
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Ethinyl Estradiol and Norethisterone
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethisterone
Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs.
Time frame: Up to 46 days
Number of Participants With Treatment- Emergent Adverse Events (TEAEs) by Severity
The Investigator assessed the severity of each AE and SAE reported during the study and assign it to one of the following categories: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities; Severe: An event that prevents normal everyday activities. Do not confuse an AE that is assessed as severe with a SAE. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe.
Time frame: Up to 46 days
Change From Baseline in Hematology Parameter: Hemoglobin at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: hemoglobin.
Time frame: Baseline, Day 18
Change From Baseline in Hematology Parameter: Erythrocytes at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes.
Time frame: Baseline, Day 18
Change From Baseline in Hematology Parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes and Lymphocytes at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes and Lymphocytes.
Time frame: Baseline, Day 18
Change From Baseline in Hematology Parameters: Hematocrit, Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Hematocrit, Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes.
Time frame: Baseline, Day 18
Change From Baseline in Coagulation Parameter: Activated Partial Thromboplastin Time at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the coagulation parameter: Activated Partial Thromboplastin Time.
Time frame: Baseline, Day 18
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin.
Time frame: Baseline, Day 18
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume.
Time frame: Baseline, Day 18
Change From Baseline in Coagulation Parameter: Prothrombin Intl. Normalized Ratio at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the coagulation parameter: Prothrombin Intl. Normalized Ratio.
Time frame: Baseline, Day 18
Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine and Urate at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: bilirubin, creatinine and urate.
Time frame: Baseline, Day 18
Change From Baseline in Chemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase.
Time frame: Baseline, Day 18
Change From Baseline in Chemistry Parameters: Sodium, Potassium, Calcium, Glucose, Chloride and Triglycerides at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Sodium, Potassium, Calcium, Glucose, Chloride and Triglycerides.
Time frame: Baseline, Day 18
Change From Baseline in Chemistry Parameters: Total Protein at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Total Protein.
Time frame: Baseline, Day 18
Change From Baseline in Chemistry Parameters: C Reactive Protein at Day 18
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: C Reactive Protein.
Time frame: Baseline, Day 18
Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure at Day 18
Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline, Day 18
Change From Baseline in Vital Signs: Pulse Rate at Day 18
Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline, Day 18
Change From Baseline in Vital Signs: Respiratory Rate at Day 18
Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline, Day 18
Change From Baseline in Vital Signs: Temperature at Day 18
Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline, Day 18
Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate at Day 18
Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions
Time frame: Baseline, Day 18
Change From Baseline in Electrocardiograms (ECGs) Parameter: RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration at Day 18
RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline, Day 18
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ethinyl Estradiol and Norethisterone
Time to reach the maximum observed plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Terminal Half Life (T1/2) of Ethinyl Estradiol and Norethisterone
Terminal half-life was calculated as log2 divided by lambda z. Lambda z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve.
Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Ethinyl Estradiol and Norethisterone
The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ). Calculated using the mixed log-linear trapezoidal rule (linear up, log down).
Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Apparent Total Body Clearance (CL/f) of Ethinyl Estradiol and Norethisterone
Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose/AUC0-infinity for Ethinyl Estradiol/Norethisterone.
Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
Apparent Volume of Distribution During Terminal Phase (VZ/f) of Ethinyl Estradiol and Norethisterone
Vz/f is defined as the apparent volume of distribution during the terminal phase following extravascular administration for Ethinyl Estradiol/Norethisterone.
Time frame: Pre-dose, 0.3, 0.6, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours post-dose on Days 1, 2, 3, 4, 15, 16, 17 and 18
| Milestone | COC + Evobrutinib |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated serum concentration at the last sampling time point at which the measured serum concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured serum concentrations of the terminal log-linear phase.
| hour × picogram per milliliter (h×pg/mL) | COC + Evobrutinib |
|---|---|
| Ethinyl Estradiol | 1090 ± 26.7 |
| Norethisterone | 36000 ± 35.9 |
Cmax was obtained directly from the concentration versus time curve.
| pg/mL | COC + Evobrutinib |
|---|---|
| Ethinyl Estradiol | 51.8 ± 30.1 |
| Norethisterone | 4620 ± 34.0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs.
| Participants | COC + Evobrutinib |
|---|---|
| Number of Participants With Treatment- Emergent Adverse Events (TEAEs) | 9 |
The Investigator assessed the severity of each AE and SAE reported during the study and assign it to one of the following categories: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities; Severe: An event that prevents normal everyday activities. Do not confuse an AE that is assessed as severe with a SAE. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe.
| Participants | COC + Evobrutinib |
|---|---|
| Mild | 8 |
| Moderate | 1 |
| Severe | 0 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: hemoglobin.
| gram per liter (g/L) | COC + Evobrutinib |
|---|---|
| Change From Baseline in Hematology Parameter: Hemoglobin at Day 18 | -8.780 ± 7.7256 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes.
| 10^12 cells per liter | COC + Evobrutinib |
|---|---|
| Change From Baseline in Hematology Parameter: Erythrocytes at Day 18 | -0.29 ± 0.263 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes and Lymphocytes.
| 10^9 cells per liter | COC + Evobrutinib |
|---|---|
| Platelets | -18 ± 38.0 |
| Leukocytes | -0.08 ± 1.395 |
| Neutrophils | -0.21 ± 1.390 |
| Eosinophils | -0.00 ± 0.050 |
| Basophils | 0.00 ± 0.017 |
| Monocytes | -0.02 ± 0.110 |
| Lymphocytes | 0.16 ± 0.338 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Hematocrit, Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes.
| percentage of cells | COC + Evobrutinib |
|---|---|
| Hematocrit | -0.029 ± 0.0227 |
| Basophils/Leukocytes | 0.0 ± 0.30 |
| Eosinophils/Leukocytes | 0.0 ± 0.63 |
| Lymphocytes/Leukocytes | 3.2 ± 8.44 |
| Monocytes/Leukocytes | -0.2 ± 1.34 |
| Neutrophils/Leukocytes | -3.0 ± 9.30 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the coagulation parameter: Activated Partial Thromboplastin Time.
| seconds | COC + Evobrutinib |
|---|---|
| Change From Baseline in Coagulation Parameter: Activated Partial Thromboplastin Time at Day 18 | -1.6 ± 0.84 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin.
| picogram | COC + Evobrutinib |
|---|---|
| Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin at Day 18 | -0.06283 ± 0.541316 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume.
| femtoliters | COC + Evobrutinib |
|---|---|
| Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume at Day 18 | -0.7 ± 0.95 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the coagulation parameter: Prothrombin Intl. Normalized Ratio.
| ratio | COC + Evobrutinib |
|---|---|
| Change From Baseline in Coagulation Parameter: Prothrombin Intl. Normalized Ratio at Day 18 | -0.02 ± 0.042 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: bilirubin, creatinine and urate.
| micromole per liter (mcmol/L) | COC + Evobrutinib |
|---|---|
| Bilirubin | -0.8 ± 3.11 |
| Creatinine | -4 ± 6.2 |
| Urate | 4.1 ± 31.48 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase.
| units per liter (U/L) | COC + Evobrutinib |
|---|---|
| Aspartate Aminotransferase | -2 ± 6.2 |
| Alanine Aminotransferase | 3 ± 11.8 |
| Alkaline Phosphatase | -4 ± 10.1 |
| Amylase | -1 ± 7.5 |
| Lipase | -2.0 ± 7.77 |
| Gamma Glutamyl Transferase | 0 ± 5.4 |
| Lactate Dehydrogenase | -35 ± 19.7 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Sodium, Potassium, Calcium, Glucose, Chloride and Triglycerides.
| millimoles per liter (mmol/L) | COC + Evobrutinib |
|---|---|
| Sodium | 1 ± 2.6 |
| Potassium | -0.03 ± 0.397 |
| Calcium | -0.04 ± 0.077 |
| Glucose | -0.10 ± 0.385 |
| Chloride | 2 ± 2.4 |
| Triglycerides | 0.2 ± 0.29 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: Total Protein.
| gram per liter (g/L) | COC + Evobrutinib |
|---|---|
| Change From Baseline in Chemistry Parameters: Total Protein at Day 18 | -2 ± 3.5 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the chemistry parameter: C Reactive Protein.
| milligram per liter (g/L) | COC + Evobrutinib |
|---|---|
| Change From Baseline in Chemistry Parameters: C Reactive Protein at Day 18 | 4 ± 8.2 |
Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| millimeters of mercury (mmHg) | COC + Evobrutinib |
|---|---|
| Systolic Blood Pressure | 4 ± 12.5 |
| Diastolic Blood Pressure | 3 ± 9.7 |
Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| beats per minute | COC + Evobrutinib |
|---|---|
| Change From Baseline in Vital Signs: Pulse Rate at Day 18 | 4 ± 10.6 |
Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| breaths per minute | COC + Evobrutinib |
|---|---|
| Change From Baseline in Vital Signs: Respiratory Rate at Day 18 | 0 ± 1.5 |
Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| degree Celsius | COC + Evobrutinib |
|---|---|
| Change From Baseline in Vital Signs: Temperature at Day 18 | 0.2 ± 0.49 |
Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions
| beats per minute | COC + Evobrutinib |
|---|---|
| Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate at Day 18 | -4 ± 7.5 |
RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| milliseconds (msec) | COC + Evobrutinib |
|---|---|
| RR Duration | 51 ± 98.4 |
| QT Duration | 3 ± 17.8 |
| QTcF Duration | -5 ± 11.0 |
| PR Duration | 3 ± 15.3 |
| QRS Duration | -2 ± 9.6 |
Time to reach the maximum observed plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| hours | COC + Evobrutinib |
|---|---|
| Ethinyl Estradiol | 3.00 (1.50 to 6.02) |
| Norethisterone | 2.00 (0.667 to 3.00) |
Terminal half-life was calculated as log2 divided by lambda z. Lambda z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve.
| hours | COC + Evobrutinib |
|---|---|
| Ethinyl Estradiol | 21.5 (10.5 to 32.1) |
| Norethisterone | 12.7 (7.58 to 20.9) |
The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ). Calculated using the mixed log-linear trapezoidal rule (linear up, log down).
| h×pg/mL | COC + Evobrutinib |
|---|---|
| Ethinyl Estradiol | 964 ± 26.9 |
| Norethisterone | 35100 ± 36.4 |
Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose/AUC0-infinity for Ethinyl Estradiol/Norethisterone.
| Liter per hour | COC + Evobrutinib |
|---|---|
| Ethinyl Estradiol | 27.6 ± 26.7 |
| Norethisterone | 13.9 ± 35.9 |
Vz/f is defined as the apparent volume of distribution during the terminal phase following extravascular administration for Ethinyl Estradiol/Norethisterone.
| Liter | COC + Evobrutinib |
|---|---|
| Ethinyl Estradiol | 816 ± 26.0 |
| Norethisterone | 252 ± 46.7 |
Collected over Up to 46 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| COC + Evobrutinib | 0/20 (0%) | 0/20 (0%) | 9/20 (45%) |
| Event | COC + Evobrutinib |
|---|---|
| PollakiuriaRenal and urinary disorders | 6/20 |
| Abnormal faecesGastrointestinal disorders | 1/20 |
| Defaecation urgencyGastrointestinal disorders | 1/20 |
| FlatulenceGastrointestinal disorders | 1/20 |
| Gastrointestinal disorderGastrointestinal disorders | 1/20 |
| FatigueGeneral disorders | 1/20 |
| NasopharyngitisInfections and infestations | 1/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/20 |
| HeadacheNervous system disorders | 1/20 |
| Age, Continuous(Years) | COC + Evobrutinib |
|---|---|
| Mean | 57 ± 6.8 |
| Sex: Female, Male(Participants) | COC + Evobrutinib |
|---|---|
| Female | 20 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | COC + Evobrutinib |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | COC + Evobrutinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website http://bit.ly/IPD21
Ran from Aug 2022 to primary completion in Nov 2022, 3 months.
Results were first posted in Nov 2025, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Contraceptives, Oral, Combined
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →